Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

125 та иш

Иш: Therapeutic targeting of cancer stem cell-specific surface glycans and glycoproteins

  1. Cancer Stem Cell Metabolism

    Fidelia B. Alvina, Arvin M. Gouw, Anne Le

    Мақола20213 иқтибос
    ABI
  2. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

    X. Xia, Zongxin Yang, Qisi Lu +6

    Шарҳ мақола20242 иқтибос
    ABI
  3. Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy

    Asha Borah, Sreejith Raveendran, Ankit Rochani +2

    Шарҳ мақола20152 иқтибос
    ABI
  4. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype

    Erik Ames, Robert J. Canter, Steven K. Grossenbacher +11

    Мақола20152 иқтибос
    ABI
  5. Cancer stem cells

    Zuoren Yu, Timothy G. Pestell, Michael P. Lisanti +1

    Шарҳ мақола20122 иқтибос
    ABI
  6. Overcoming Antigen Escape with CAR T-cell Therapy

    Hollie J. Jackson, Renier J. Brentjens

    Бошқа20152 иқтибос
    ABI
  7. Circulating tumor cells in neuroblastoma: Current status and future perspectives

    Ran Yang, Shan Zheng, Rui Dong

    Шарҳ мақола20222 иқтибос
    ABI
  8. Co-opting signalling molecules enables logic-gated control of CAR T cells

    Aidan M. Tousley, Maria Caterina Rotiroti, Louai Labanieh +15

    Мақола20232 иқтибос
    ABI
  9. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects

    Yufei Wang, Alicia Buck, Brandon Piel +26

    Мақола20242 иқтибос
    ABI
  10. Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy

    Gyas Khan, Ali Hanbashi, Wedad Mawkili +7

    Мақола20252 иқтибос
    ABI
  11. The Investigation of Nfκb Inhibitors to Block Cell Proliferation in OSCC Cells Lines

    Yuxi Cheng, Liping Wang, Shuju Zhang +4

    Мақола20242 иқтибос
    ABI
  12. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

    Changsong Qi, Chang Liu, Jifang Gong +21

    Мақола20242 иқтибос
    ABI
  13. Limits of CD133 as a marker of glioma self‐renewing cells

    Virginie Clément, Valérie Dutoit, Denis Marino +2

    Мақола20092 иқтибос
    ABI
  14. Role of TRPM2 in brain tumours and potential as a drug target

    Delphine Ji, Zhengwei Luo, Andrea Ovcjak +4

    Шарҳ мақола20212 иқтибос
    ABI
  15. Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43

    Franca Maria Tuccillo, Annamaria de Laurentiis, Camillo Palmieri +8

    Шарҳ мақола20142 иқтибос
    ABI
  16. Biology and clinical relevance of EpCAM

    Laura Keller, Stefan Werner, Klaus Pantel

    Шарҳ мақола20192 иқтибос
    ABI